Sign in
Taking peopleNo phase

Fibrinolysis Resistance in Infection and Trauma

Key facts

Who runs it
Anders Aneman
Where
Australia4 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
150 people, planned
Started
1 Jun 2024
Planned end
1 Jun 2026
Type of study
Observational, 2 groups
Treatments tested
  • Viscoelastometric assessment of fibrinolysis
Record updated
8 November 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 14 criteriaShow less

Other criteria

  • Sepsis/Septic shock Inclusion Criteria:
  • Admission to ICU, needing at least one organ supportand principally for the management of clinically suspected Sepsis or Septic shock according to Spesis-3 criteria (including SARS-COV-2)
  • Expected to remain in ICU and survive beyond the day after tomorrow; Sepsis Exclusion Criteria:
  • On oral anticoagulant/antiplatelet therapy
  • Not for full, active ICU support
  • Death is deemed inevitable within 24 hrs; Trauma Inclusion Criteria:
  • Trauma is the principal diagnosis on ICU admission
  • Expected to remain in ICU and survive beyond the day after tomorrow
  • Receiving respiratory support at the time of ICU admission - high-flow nasal prongs, non-invasive or invasive ventilation
  • Already received, or considered at risk of needing a blood product transfusion within 24 hrs of injury; Trauma Exclusion Criteria:
  • Nursing home resident
  • Unsurvivable head injury
  • Not for full, active ICU support
  • Death is deemed inevitable within 24 hrs

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Blood coagulation disorders are often seen in critically ill patients e.g. with severe infection or following extensive injury, that can lead to life threatening events as a result of excessive blood clot formation leading to organ failure. This study aims to use Viscoelastic Testing (VET) technology to detect patients at risk of excessive blood blot formation at the bedside, test new blood coagulation drugs, and guide life-saving use of blood modifying treatments.

The 2 groups in the trial

  • Sepsis/Septic shock

    According to Sepsis-3 definitions (including SARS CoV-2 as pathogen); expected to remain in ICU and survive beyond the day after tomorrow and for full, active ICU treatment; arterial and secure venous access established or imminent as part of standard care; not on oral anticoagulant/antiplatelet therapy.

    Treatment: Viscoelastometric assessment of fibrinolysis

  • Severe Trauma

    Admitted via the Emergency Department resuscitation bay requiring trauma team response; deemed at risk of significant blood loss and where transfusion of blood products i considered in the ED during the acute phase of the resuscitation by a senior clinician; expected to remain in ICH and survive beyond the day after tomorrow and for full, active ICU treatment; Not on oral anticoagulant/antiplatelet therapy. A clinical based inclusion approach is the most pragmatic means of patient selection and can be objectively supported by routine blood tests demonstrating poor oxygen supply to the organs. Exclusion criteria: unsurvivable head injury.

    Treatment: Viscoelastometric assessment of fibrinolysis

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
8 November 2024